New vaccine study aims to shield vulnerable kids from pneumonia
NCT ID NCT07252791
First seen Dec 08, 2025 · Last updated May 05, 2026 · Updated 19 times
Summary
This study is testing a 20-valent pneumococcal conjugate vaccine (PCV20) in 114 children, adolescents, and young adults aged 2-25 who have autoimmune rheumatic diseases like juvenile arthritis. The goal is to see if the vaccine is safe and helps their immune system fight pneumococcal bacteria. Participants will receive the vaccine based on their past shots, and researchers will measure immune responses and side effects for up to 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE RHEUMATOLOGIC DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital das Clinics da Faculdade de Medicina da Universidade de Sao Paulo
RECRUITINGSão Paulo, São Paulo, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.